Dolutegravir with tenofovir disoproxil fumarate-emtricitabine as HIV postexposure prophylaxis in gay and bisexual men

Objectives: Completion rates for HIV postexposure prophylaxis (PEP) are often low. We investigated the adherence and safety of dolutegravir (DTG; 50mg daily) with tenofovir disoproxil fumarate-emtricitabine (TDF-FTC; 300/200 mg, respectively) as three-drug PEP in gay and bisexual men. Design: Open-label, single-arm study at three sexual health clinics and two emergency departments in Australia. Methods: In total, 100 HIV-uninfected gay and bisexual men requiring PEP received DTG and TDF-FTC for 28 days. The primary end point was PEP failure (premature PEP cessation or primaryHIVinfection throughweek 12). Additional end pointswere adherence by self-report (n = 98) and pill count (n = 55), safety, and plasma drug levels at day 28. Results: PEP completion was 90% (95% confidence interval 84-96%). Failures (occurring at a median 9 days, interquartile range 3-16) comprised loss to follow-up (9%) and adverse event resulting in study drug discontinuation (headache, 1%). No participant was found to acquire HIV through week 12. Adherence to PEP was 98% by self-report and in the 55 participants with corresponding pill count data. The most common clinical adverse events were fatigue (26%), nausea (25%), diarrhoea (21%), and headache (10%). There were only four grade 3-4 subjective adverse events. The most common laboratory adverse event was raised alanine aminotransferase (22%), but there was no case of clinical hepatitis. At day 28, the mean estimated glomerular filtration rate decrease was 14 ml/min/1.73m(2) (SD 17, P = 0.001); an estimated glomerular filtration rate of less than 60 ml/min/1.73m(2) occurred in 3%. Conclusions: DTG with TDF-FTC is a well tolerated option for once-daily PEP. Copyright (C) 2017 Wolters Kluwer Health, Inc. All rights reserved.